Walleye Capital’s Viking Therapeutics VKTX Stock Holding History

Walleye Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.07M	Sell	33,000 -67,800	-67%	-$2.18M	﹤0.01%	2012
2025 Q4	$3.55M	Buy	100,800 +10,100	+11%	+$358K	0.01%	1410
2025 Q3	$2.38M	Buy	90,700 +58,700	+183%	+$1.75M	0.01%	1452
2025 Q2	$848K	Sell	32,000 -1,200	-4%	-$31.6K	﹤0.01%	2180
2025 Q1	$802K	Sell	33,200 -10,300	-24%	-$326K	﹤0.01%	2160
2024 Q4	$1.75M	Sell	43,500 -5,300	-11%	-$302K	﹤0.01%	1904
2024 Q3	$3.09M	Buy	48,800 +32,300	+196%	+$1.9M	0.01%	1557
2024 Q2	$875K	Buy	16,500 +7,900	+92%	+$518K	﹤0.01%	2988
2024 Q1	$705K	Sell	8,600 -28,800	-77%	-$1.28M	﹤0.01%	2902
2023 Q4	$696K	Buy	+37,400	New	+$489K	﹤0.01%	2677
2023 Q3	–	Sell	-8,600	Closed	-$139K	–	5356
2023 Q2	$139K	Sell	8,600 -5,300	-38%	-$111K	﹤0.01%	3286
2023 Q1	$231K	Buy	+13,900	New	+$144K	﹤0.01%	2346

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Walleye Capital's VKTX Position: Q1 2026 in Review

Walleye Capital reduced its Viking Therapeutics (VKTX) stake by 95% in Q1 2026, selling an estimated $2.63M and leaving 4,573 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #3499.

Walleye Capital first reported a position in VKTX in Q3 2018 and has held it in 17 quarters since. The position peaked at $3.04M in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Walleye Capital held 4,573 shares of Viking Therapeutics worth $149K as of Q1 2026.
Walleye Capital sold 81,798 Viking Therapeutics shares in Q1 2026, an estimated $2.63M.
Viking Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3499 holding.
Walleye Capital first reported a position in Viking Therapeutics in Q3 2018 and has held it in 17 quarters since.
Walleye Capital's Viking Therapeutics position peaked at $3.04M in Q4 2025.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.